EICHORCondition: Early PCSK9 Inhibitor on Ventricular Remodling · Sponsor: Shanghai Tong Ren Hospital
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.
This description comes directly from the study's public registry record.
Lei Hou, Doctor · 13564868096 · Dr_houlei@163.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Subject must be at least 18 years of age and less than 80 years old 2. Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for AMI and LAD should be the only culprit vessel. 3. Subject understand the study requirements and the treatment procedures and provided informed consent before the procedure Exclusion Criteria: 1. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study 2. Known hypersensitivity or contraindication to study medications 3. Plan to receive revascularization in next six month. 4. Have received revascularization before. 5. Subjects with life expectation less than one year. 6. Subjects with active malignant tumor 7. subjects with severe liver or renal dysfunction（ALT \>5倍ULA，eGFR\<15ml/min/1.73mm2） 8. Other conditions which the investigators think not applicable to the study.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Tongren Hospital, Shanghai | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai tenth people's hospital | Shanghai, China | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04731155